Summary:
- The article presents updated clinical trial data confirming that the Pfizer-BioNTech COVID-19 vaccine maintains high efficacy (91.3%) and a favorable safety profile for up to six months following the second dose.
- The study provides critical longitudinal evidence regarding the durability of mRNA-based vaccine protection and the absence of new, serious safety concerns in a large-scale cohort.